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Background
 
Among physicians who treat patients
with acute myocardial infarction, there is controver-
sy about the magnitude of the clinical benefit of pri-
mary (i.e., immediate) coronary angioplasty as com-
pared with thrombolytic therapy.
 
Methods
 
As part of the Global Use of Strategies to
Open Occluded Coronary Arteries in Acute Coronary
Syndromes (GUSTO IIb) trial, we randomly assigned
1138 patients from 57 hospitals who presented with-
in 12 hours of acute myocardial infarction (with
ST-segment elevation on the electrocardiogram) to
primary angioplasty or accelerated thrombolytic ther-
apy with recombinant tissue plasminogen activator
(t-PA). We also randomly assigned 1012 patients to
heparin or hirudin treatment in a factorial design.
The primary study end point was a composite out-
come of death, nonfatal reinfarction, and nonfatal
disabling stroke at 30 days.
 
Results
 
The incidence of the primary end point in
the angioplasty and t-PA groups was 9.6 percent and
13.7 percent, respectively (odds ratio, 0.67; 95 per-
cent confidence interval, 0.47 to 0.97; P
 

 
0.033). Death
occurred in 5.7 percent of the patients assigned to an-
gioplasty and 7.0 percent of those assigned to t-PA
(P
 

 
0.37), reinfarction in 4.5 percent and 6.5 percent
(P
 

 
0.13), and disabling stroke in 0.2 percent and 0.9
percent (P
 

 
0.11). At six months, there was no signif-
icant difference in the incidence of the composite
outcome (14.1 percent vs. 16.1 percent, P not signifi-
cant). The primary end point was observed in 10.6
percent of the patients in the angioplasty group as-
signed to heparin and 8.2 percent of those assigned
to hirudin (P
 

 
0.37).
 
Conclusions
 
This trial suggests that angioplasty
provides a small-to-moderate, short-term clinical ad-
vantage over thrombolytic therapy with t-PA. Primary
angioplasty, when it can be accomplished promptly
at experienced centers, should be considered an ex-
cellent alternative method for myocardial reperfu-
sion. (N Engl J Med 1997;336:1621-8.)
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ROMPT, complete restoration of coronary
flow is the principal mechanism by which re-
perfusion therapy improves survival and oth-
er clinical outcomes in patients with acute
myocardial infarction in whom there is electrocar-
diographic evidence of ST-segment elevation.
 
1-3
 
 At
selected centers, coronary angioplasty can be per-
formed expeditiously in such patients, resulting in
better coronary flow
 
4,5
 
 and 30-day survival rates
 
2,4-12
 
than are obtained with intravenous thrombolytic
therapy.
Intravenous thrombolytic therapy is, however, the
standard of care for patients with acute myocardial
infarction, because of its widespread availability, its
ability to reduce mortality, and its use in more than
a million patients over the past decade.
 
6,13-15
 
 Recently,
two large studies of registry data
 
16,17
 
 raised doubt
about whether the apparent superiority of angio-
plasty over thrombolytic therapy would be sustained
in general clinical practice, because treatment delays
and technical failures appear to be more common
than in the selected centers that have participated in
randomized trials.
The use of “front-loaded” (accelerated), weight-
adjusted treatment with recombinant tissue plasmin-
ogen activator (t-PA)
 
6
 
 instead of other lytic regimens
used in previous trials
 
4,5,7-12
 
 might further reduce the
differences in outcome between these two therapies.
Also, the adjunctive use of direct inhibitors of throm-
bin, which have several potential advantages over
heparin but have not been proved beneficial in this
setting,
 
18,19
 
 might also influence the outcomes of
these two strategies. Therefore, we performed an in-
P
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ternational, multicenter, randomized trial compar-
ing primary angioplasty with thrombolytic therapy
(and hirudin with heparin, in the patients treated
with primary angioplasty) in the initial management
of acute myocardial infarction.
 
METHODS
 
Study Organization
 
This study was a prospective substudy of the Global Use of Strat-
egies to Open Occluded Coronary Arteries in Acute Coronary Syn-
dromes (GUSTO IIb) trial.
 
20
 
 Fifty-seven hospitals in nine countries
participated (see the Appendix). To participate, each site was re-
quired to perform at least 200 angioplasties yearly, to have at least
one cardiologist who had performed at least 50 angioplasties year-
ly, a 24-hour on-call team, and a system for operating-room back-
up if emergency bypass surgery was required. Eighty-five percent of
sites performed more than 400 angioplasties yearly, and 85 percent
of operators performed more than 75 angioplasties yearly.
 
Study Patients
 
Patients presenting within 12 hours after the onset of symp-
toms (chest pain lasting at least 20 minutes, accompanied by elec-
trocardiographic signs of ST-segment elevation of at least 0.2 mV
in two or more contiguous leads or left bundle-branch block)
were eligible for enrollment. The exclusion criteria were identical
to those used in the main GUSTO IIb trial.
 
20
 
 All the patients gave
informed consent, and the protocol was approved by the institu-
tional review board at each hospital.
 
Randomization and Treatment Strategies
 
The investigators and study coordinators telephoned or faxed a
24-hour-a-day, seven-day-a-week randomization center to review
the eligibility of patients and receive their assignments to treat-
ment. Eligible patients were randomly assigned to either primary
coronary angioplasty or accelerated t-PA (an intravenous bolus of
15 mg, followed by an infusion of 0.75 mg per kilogram of body
weight [not to exceed 50 mg] over a 30-minute period and then
0.50 mg per kilogram [not to exceed 35 mg] over the next 60
minutes, for a maximal total dose of 100 mg). The first 1012
patients were also randomly assigned, in a two-by-two factorial de-
sign, to either heparin or hirudin given intravenously as part of the
GUSTO IIb trial (these patients were included in the main tri-
al).
 
20
 
 The protocol for the administration of the study drug in this
trial has been reported previously
 
20
 
; in brief, patients were as-
signed to receive an infusion of either heparin or hirudin for three
to five days; the dose was adjusted to keep the activated partial-
thromboplastin time within the 60-to-85-second range.
At the recommendation of the Data and Safety Monitoring
Board and the GUSTO IIb Steering Committee, enrollment in
this substudy was extended, without a review of the end-point da-
ta, beyond the completion of enrollment in the GUSTO IIb trial,
to January 1, 1996, in order to reach the intended sample size.
All the patients enrolled thereafter were treated with heparin as
the thrombin inhibitor.
All the patients were also to receive standard medical care,
including chewable aspirin, at the time of enrollment.
 
20
 
 Other car-
diac medications were administered at the discretion of the phy-
sician. Angiography within three days of study entry was discour-
aged in patients randomly assigned to t-PA, except to manage
refractory ischemia or hemodynamic deterioration.
 
Primary Angioplasty
 
Angioplasty was performed according to local standards, with
the intention of reestablishing blood flow in the infarct-related ar-
tery as soon as possible. After securing arterial access and verifying
that angioplasty was indicated, we titrated the study thrombin in-
hibitor in a double-blind fashion in increments of 3000 U of hep-
arin or 30 mg of hirudin to reach an activated clotting time of at
least 350 seconds. The infarct-related artery was the only target,
except in patients whose hemodynamic values deteriorated de-
spite restoration of the patency of that artery. After angioplasty,
the study drug was temporarily stopped to permit early removal
of the sheath. The study protocol acknowledged that in some pa-
tients, particularly those with stenoses of the left main artery or
critical three-vessel disease, bypass surgery should be strongly
considered instead of angioplasty. In patients whose infarct-relat-
ed arteries had Thrombolysis in Myocardial Infarction (TIMI)
grade 3 flow at first angiography, whether or not to perform an-
gioplasty was left to the judgment of the operator.
 
Angiographic Analyses
 
The cineangiograms obtained at study entry for all patients ran-
domly assigned to angioplasty were forwarded to the Angiographic
Core Laboratory for quantitative analyses by a validated edge-
detection method (Artrek, version 1.60, Quinton Imaging Systems,
Bothell, Wash.).
 
21
 
 Technical success was defined as a residual steno-
sis of less than 50 percent and a final TIMI flow grade of 2 or 3.
 
Data Management and Quality Assurance
 
Case-report forms were forwarded to either the international
coordinating center (Catholic University, Leuven, Belgium) or
the main coordinating center (Duke University, Durham, N.C.)
for data entry and the generation of queries about missing or in-
consistent data. Patient follow-up at 30 days and 6 months was
performed by means of a self-administered questionnaire, tele-
phone interview, or follow-up visit to the physician. The quality
of the data was ensured by auditing 10 percent of the data forms
and by having an independent Clinical Events Committee adju-
dicate decisions on all possible primary-end-point events. A data-
based algorithm was developed to capture all the events that
might constitute part of the primary end point and trigger a re-
view of chart information by this committee, whose members re-
mained unaware of the initial treatment assignments.
 
End Points
 
The primary end point was a composite outcome of death,
nonfatal reinfarction, and nonfatal disabling stroke within 30
days, as confirmed by the Clinical Events Committee. The prespec-
ified secondary end points were mortality from all causes at 30
days; mortality from all causes and nonfatal reinfarction at 30 days;
a composite end point consisting of death, reinfarction, disabling
stroke, and congestive heart failure at 30 days; recurrent, medical-
ly refractory ischemia; and major bleeding.
 
20
 
 Follow-up electro-
cardiograms and creatine kinase and MB isoenzyme levels were
to be obtained at the time of any suspected myocardial reinfarc-
tion.
 
20
 
 Computed tomography or magnetic resonance imaging of
the brain was requested for all patients with suspected stroke. Se-
vere bleeding was defined as intracranial hemorrhage or bleeding
that caused hemodynamic compromise. Moderate bleeding was
defined as bleeding that required blood transfusion but that did
not lead to hemodynamic compromise.
 
Statistical Analysis
 
The primary study hypothesis was that immediate angioplasty
would result in a lower incidence of death, nonfatal reinfarction,
and nonfatal disabling stroke at 30 days than thrombolytic ther-
apy. The incidence of the primary end point in the t-PA group
was expected to be approximately 12 percent. Although studies
had suggested that the incidence of major end points would be
more than 60 percent lower with angioplasty than with throm-
bolytic therapy,
 
4,5,7-12
 
 the size of this study population was chosen
to ensure that a relative reduction of 40 percent could be detect-
ed with an alpha error of 0.05 and a beta error of 0.20.
Continuous data are presented as medians with 25th and 75th
percentiles unless otherwise stated. Selected base-line character-
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istics and clinical outcomes were compared between treatment
groups by the chi-square test in the case of discrete variables and
by nonparametric analysis of variance in the case of continuous var-
iables. Odds ratios and 95 percent confidence intervals were used
to compare treatments with regard to major clinical outcomes. Kap-
lan–Meier survival curves were used to characterize the timing of
the primary study end point and its components during the follow-
up period. Logistic-regression models were used to assess prespec-
ified interactions.
Prespecified subgroups classified according to the following
variables were studied in relation to the primary and secondary end
points: age and time to randomization, as continuous variables;
and anterior as compared with nonanterior location of the infarct,
high as compared with low risk,
 
5
 
 and the hospital’s experience with
angioplasty (with the number of procedures dichotomized at the
median), as discrete variables.
An interim analysis of safety was performed by an independent
Data and Safety Monitoring Board when the enrollment reached
750 patients, as specified in the protocol. Efficacy was compared
with the use of two-sided, symmetric O’Brien–Fleming boundaries
generated by the Lan–DeMets approach to group-sequential test-
ing.
 
22,23
 
 All tests of significance were two-tailed, and the treatments
were compared according to the intention-to-treat principle.
 
RESULTS
 
Recruitment began on July 5, 1994, and ended
on January 1, 1996, after 1138 patients had been
enrolled. The patients tended to be middle-aged and
male, presenting without hypotension or pulmonary
edema (Table 1). Among the patients randomly as-
signed to angioplasty, 94 percent had angiography
and 82 percent had angioplasty (5 percent also re-
ceived stents); among the patients randomly as-
signed to t-PA, 98 percent received that therapy and
only 1.4 percent had primary angioplasty. Balloon
inflation was first performed in the patients under-
going angioplasty a median of 1.3 hours after ran-
domization (interquartile range, 1.0 to 1.6). The ac-
tivated partial-thromboplastin times at 6 hours were
longer in the angioplasty group because of peripro-
cedural dosing to achieve an activated clotting time
of more than 350 seconds, but the times in the two
groups were similar by 12 hours after the initial drug
therapy. 
In the patients randomly assigned to angioplasty,
83 percent of the infarct-related arteries were initial-
ly occluded (TIMI grade 0 or 1 flow) according to
the on-site interpretation (Table 2). The median peak
activated clotting time during the procedure was
381 seconds (interquartile range, 329 to 480). TIMI
grade 3 flow was obtained in 73 to 88 percent of the
patients (depending on whether the angiograms were
read at the core laboratory or at the site). Seventeen
of 465 patients (3.7 percent) who were randomly as-
 
*Median values are given with interquartile ranges (the 25th and 75th percentiles).
†Data were not available for some patients.
‡Times shown are from the onset of symptoms.
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.*
 
C
 
HARACTERISTIC
 
t-PA
(N
 

 
573)
A
 
NGIOPLASTY
 
(N
 

 
565)
H
 
EPARIN
 
 
 
PLUS
 
A
 
NGIOPLASTY
 
(N
 

 
247)
H
 
IRUDIN
 
 
 
PLUS
 
A
 
NGIOPLASTY
 
(N
 

 
256)
 
Median age — yr 61.9 (52.0, 70.1) 63.5 (52.5, 71.0) 64 (50, 71) 63 (54, 71)
Age 
 

 
75 yr — no. (%) 79 (13.8) 82 (14.5) 32 (13.0) 39 (15.2)
Female sex — no.(%) 121 (21.5) 139 (24.6) 65 (26.3) 66 (25.8)
Current smoker — no. (%)† 255 (60.9) 235 (63.7) 102 (61.1) 108 (69.2)
Diabetes — no. (%)† 77 (13.4) 99 (17.5) 45 (18.2) 50 (19.5)
Median heart rate — beats/min 74.5 (62, 86) 75 (63, 87) 75 (63, 87) 75 (64, 86)
Hypertension — no. (%)† 218 (38.0) 225 (39.8) 100 (40.5) 101 (39.5)
Killip class — no. (%)†
1
2
3
4
524 (91.4)
41 (7.2)
4 (0.7)
2 (0.3)
507 (89.7)
47 (8.3)
2 (0.4)
5 (0.9)
220 (89.1)
22 (8.9)
1 (0.4)
3 (1.2)
228 (89.1)
23 (9.0)
1 (0.4)
2 (0.8)
Prior bypass surgery — no. (%) 16 (2.8) 12 (2.1) 2 (0.8) 10 (3.9)
Prior myocardial infarction 
— no. (%)†
85 (14.8) 73 (12.9) 25 (10.1) 38 (14.8)
Prior angioplasty — no. (%) 28 (4.9) 29 (5.1) 9 (3.6) 17 (6.6)
Median systolic blood pressure 
— mm Hg
130 (116, 148) 130 (116, 147) 130 (118, 150) 130 (113, 144)
Median time to arrival at hospital
— hr‡
1.8 (1.0, 3.1) 1.9 (1.1, 3.0) 2.0 (1.1, 3.2) 1.9 (1.2, 2.8)
Median time to treatment — hr‡ 3 (2.0, 4.3) 3.8 (3.0, 5.3) 3.9 (3.0, 5.4) 3.9 (3.0, 5.1)
Median weight — kg 76 (68, 86) 75 (67, 86) 76 (67, 86) 75 (67, 86)
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signed to angioplasty and who underwent that pro-
cedure required bypass surgery on the same day. The
results of angioplasty did not differ significantly be-
tween the patients assigned to heparin and those as-
signed to hirudin. The medications received during
hospitalization are shown in Table 3.
As compared with t-PA, angioplasty resulted in 13
fewer deaths (95 percent confidence interval, 
 

 
15 to
41; P
 

 
0.37) and 41 fewer deaths, infarctions, or
disabling strokes (95 percent confidence interval, 3 to
78; P
 

 
0.033) at day 30 per 1000 patients (Tables
4 and 5). Most of the relative benefit of angioplasty
seemed to occur between days 5 and 10 (Fig. 1).
Among patients undergoing delayed elective angio-
plasty, 7 of 61 (11 percent) in the t-PA group and
2 of 5 (40 percent) in the angioplasty group subse-
quently died or had a reinfarction or a nonfatal, dis-
abling stroke. Angioplasty was associated with more
bleeding events than t-PA, with the notable exception
of intracranial hemorrhage. Death, reinfarction, or
disabling stroke occurred in 10.6 percent of patients
assigned to angioplasty and heparin, as compared
with 8.2 percent of those assigned to angioplasty and
hirudin (P
 

 
0.37). Bleeding complications in the
hirudin and heparin groups were similar.
Eighteen percent of the patients assigned to an-
gioplasty did not undergo that procedure. At least
9.3 percent had acceptable reasons for not undergo-
ing primary angioplasty: 1.2 percent died early, 6.9
percent had an open infarct-related artery, and 1.2
percent had early bypass surgery with left main or
three-vessel coronary disease. Another 3.4 percent
had early catheterization with no reason noted for
refraining from primary angioplasty; 3.6 percent
did not undergo early catheterization, had received
thrombolytic therapy before catheterization (often
because of delays in patient transfer), or both; and for
the remaining 1.6 percent, information about the
time of catheterization was missing. Among the pa-
tients assigned to primary angioplasty who did not
undergo the procedure, 14.1 percent died within 30
days and 20.7 percent died or had a nonfatal rein-
farction or nonfatal, disabling stroke. 
In the angioplasty group, the correlations between
mortality within 30 days and the final TIMI flow
grades as determined in the core laboratory were as
follows: TIMI flow grade 0, 21.4 percent mortality;
grade 1, 14.3 percent; grade 2, 19.9 percent; and
grade 3, 1.6 percent (P
 

 
0.001).
The relation between the risk of death within 30
days and assignment to angioplasty or accelerated
t-PA in several prospectively defined subgroups of
patients is shown in Figure 2. 
Six months after randomization, with follow-up
complete in 96.9 percent of the eligible patients, the
incidence of the composite adverse outcome was
15.7 percent in the t-PA group and 13.3 percent in
the angioplasty group (P not significant).
 
*Median values are given with interquartile ranges (the 25th and 75th
percentiles).
†Data were not available for some patients.
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Before angioplasty 
 
Median percent stenosis 100 (81.9, 100) 100 (99, 100)
TIMI flow grade — no. (%)
0
1
2
3
0 or 1
2 or 3
308 (60.4)
66 (12.9)
96 (18.8)
40 (7.8)
—
—
325 (70.3)
52 (11.3)
40 (8.7)
37 (8.0)
4 (0.9)
4 (0.9)
 
After angioplasty
 
Median percent stenosis
 

 
50% stenosis — no. (%)
 

 
60% stenosis — no. (%)
39.2 (30.7, 48.8)
343 (77.4)
406 (91.7)
23 (10, 30)
423 (91.4)
438 (94.6)
TIMI flow grade — no. (%)
0
1
2
3
Open (TIMI 2 or 3, not 
specified)
28 (5.5)
7 (1.4)
101 (19.9)
372 (73.2)
—
12 (2.7)
9 (2.0)
32 (7.1)
385 (85.4)
13 (2.9)
Peak intraprocedural activated 
clotting time — sec
— 381 (329, 480)
*In these patients, heparin was given before infusion of the study drug.
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 CONCOMITANT MEDICATIONS AND IN-HOSPITAL 
PROCEDURES IN THE STUDY GROUPS.
MEDICATION OR PROCEDURE t-PA ANGIOPLASTY
no. of patients (%)
Angiotensin-converting–enzyme inhibitor 253 (45.1) 225 (40.3)
Aspirin 559 (98.1) 550 (98.0)
Beta-blocker
Intravenous
Oral
171 (30.1)
409 (72.7)
151 (26.9)
388 (69.9)
Calcium-channel blocker 163 (29.1) 158 (28.4)
Digitalis 61 (10.8) 72 (12.9)
Nitrate
Intravenous 
Oral
491 (86.3)
427 (76.1)
468 (83.1)
410 (74.0)
Nonstudy heparin* 267 (51.1) 208 (40.7)
Warfarin 80 (14.1) 61 (11.0)
Angiography
Emergency
Elective
Specified by protocol
None
82 (14.4)
270 (47.3)
6 (1.1)
213 (37.3)
22 (4.0)
19 (3.5)
532 (94.4)
13 (2.3)
Coronary-artery bypass surgery 47 (8.3) 42 (7.5)
Intraaortic balloon pump 39 (6.8) 78 (13.8)
First angioplasty
Emergency
Elective
Specified by protocol
None
60 (16.8)
61 (17.0)
5 (1.4)
228 (63.7)
19 (3.5)
5 (0.9)
446 (81.1)
79 (14.4)
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*Median values are given with interquartile ranges (the 25th and 75th
percentiles).
TABLE 5. OCCURRENCE OF SECONDARY END POINTS AT 30 DAYS.
END POINT t-PA ANGIOPLASTY
Bleeding — no. (%)
Any
Severe or life-threatening
Moderate
Moderate or worse
Transfusion required
195 (34.2)
11 (1.9)
44 (7.7)
54 (9.5)
51 (8.9)
227 (40.3)
15 (2.7)
57 (10.1)
69 (12.3)
64 (11.3)
Congestive heart failure — no. (%) 28 (4.9) 24 (4.3)
Intracranial hemorrhage — no. (%) 8 (1.4) 0 
Median length of stay — days*
Intensive care unit
Hospital
3.5 (2.5, 5)
10 (7, 14)
3 (2, 4)
8 (6, 12)
Recurrent ischemia — no. (%) 48 (9.0) 29 (5.5)
Shock — no. (%) 26 (4.6) 34 (6.1)
Any stroke — no. (%) 11 (1.9) 6 (1.1)
Death, myocardial infarction, stroke, or 
congestive heart failure — no. (%)
94 (16.5) 71 (12.6)
Figure 1. Kaplan–Meier Curves for Survival (Panel A) and Free-
dom from the Composite End Point of Death, Reinfarction, and
Disabling Stroke (Panel B) in the Study Patients within the 30
Days after Randomization, According to Treatment Group.
TABLE 4. OCCURRENCE OF THE PRIMARY END POINT AT 30 DAYS.
END POINT t-PA ANGIOPLASTY
ODDS RATIO
(95% CONFIDENCE
INTERVAL)
P
VALUE
ANGIOPLASTY
PLUS
HIRUDIN
ANGIOPLASTY
PLUS
HEPARIN
ODDS RATIO
(95% CONFIDENCE
INTERVAL)
P
VALUE
no. (%) no. (%)
Death 40 (7.0) 32 (5.7) 0.80 (0.49–1.30) 0.37 12 (4.7) 15 (6.1) 0.77 (0.34–1.67) 0.50
Reinfarction 37 (6.5) 25 (4.4) 0.67 (0.40–1.12) 0.13 11 (4.3) 11 (4.5) 0.97 (0.41–2.27) 0.94
Disabling stroke 5 (0.9) 1 (0.2) 0.20 (0.02–1.73) 0.11 0 1 (0.4) — —
Any of the above 78 (13.6) 54 (9.6) 0.67 (0.47–0.97) 0.033 21 (8.2) 26 (10.6) 0.76 (0.42–1.39) 0.37
DISCUSSION
In this international trial comparing primary an-
gioplasty with thrombolytic therapy for acute my-
ocardial infarction, there was a relative benefit at
30 days with angioplasty with respect to all elements
of the primary study end point — death, reinfarc-
tion, and disabling stroke. The aggregate outcome
occurred significantly less often in the angioplasty
group — in 9.6 percent of patients, as compared
with 13.7 percent in the t-PA group (odds ratio,
0.67; P0.033). The extent of this benefit and of
the benefit with regard to mortality alone (P0.37)
was far less than was seen in eight previous, small,
randomized trials but larger than in recent data re-
ported from large registries.16,17
Previous randomized trials, albeit with consider-
able apparent heterogeneity, suggested that there
was a significant improvement in major clinical out-
comes with angioplasty, with an estimated 40 lives
saved (95 percent confidence interval, 2 to 63) per
1000 patients treated.4,5,7-12 This benefit is larger
than the benefit of streptokinase as compared with
placebo (in the Gruppo Italiano per lo Studio della
Streptochinasi nell’Infarto Miocardico trial, 23 lives
saved at 21 days; in the Second International Study
of Infarct Survival, 29 lives saved at 35 days) in the
same types of patients,13,15 a finding that revolution-
ized the care of patients with acute myocardial in-
farction. However, these trials were performed at se-
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lected hospital sites, involved few patients, and
except in one case, used thrombolytic regimens that
are suboptimal by today’s standards. 
Another difference in outcome between this and
other trials4,5 may relate to the technical results of
the angioplasty itself. Technical success, with resto-
ration of TIMI grade 3 flow, was reported in 92 to
97 percent of patients in previous trials,5,24 albeit
without independent confirmation by a core angio-
graphic laboratory. Technical success, as determined
by the core laboratory, was obtained in 93 percent
of the patients in GUSTO IIb, with TIMI grade 3
flow restored in 73 percent. These differences may
be due to the more globally representative outcome
in GUSTO IIb or to the fact that even at established
core angiographic laboratories, determinations of
TIMI flow are frequently discrepant.25 Recent re-
ported rates for the success of primary angioplasty
in the community range from 46 to 93 percent.26,27 
Although there was no significant relation between
the operator’s experience with angioplasty and the ef-
fect of treatment, 85 percent of angioplasties in this
study were performed by operators who performed
more than 75 such procedures per year. In the light
of some reports of a relation between higher volume
of angioplasty and better outcome for patients,28 the
results of this study should not be extrapolated to
operators with lower angioplasty volumes.
The results of this study also differ from those of
certain previous trials in that the patients in the high-
er-risk groups did not appear to gain greater benefit
from angioplasty. In the first Primary Angioplasty
Myocardial Infarction Study (PAMI-I),5 the patients
found in a post hoc analysis to be at high risk (those
older than 70, with anterior infarctions, or with heart
rates greater than 100 beats per minute at admission)
had a far lower in-hospital mortality with angioplasty
(2.0 percent) than patients receiving thrombolytic
therapy (10.4 percent), and others did not appear to
benefit. No significant differential effect was ob-
served in this study. It should be acknowledged that
patients at highest risk, those in Killip class 3 or 4,
are represented in very small numbers in this and
other trials.4,5 Subgroup analyses — from small trials
in particular — should be interpreted with caution,
and it will require further study to resolve this issue.
The small but definite excess of hemorrhagic strokes
with t-PA in this study is consistent with the findings
of the PAMI-I trial,5 but the risk associated with t-PA
appears to be considerably greater than what might
Figure 2. Point Estimates and 95 Percent Confidence Intervals for the Odds Ratios for Death within 30
Days in Several Prospectively Defined Subgroups of Patients, According to Treatment Assignment.
Odds ratios below 1 indicate that angioplasty is preferable, and odds ratios above 1 that thrombolysis
is preferable. High-risk patients were those with an anterior infarction, an age of 70 years or older, or
a heart rate of 100 beats per minute or higher at admission. The hospitals were subdivided according
to the median annual angioplasty caseload (625 angioplasties). The size of the solid squares corre-
sponds roughly to the number of patients studied. Complete data were not available for all the patients.
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be expected on the basis of the findings of far larger
studies6 (e.g., 1.4 percent in this substudy, as com-
pared with 0.5 percent in the main study20). This
finding may be a reason to suggest that angioplasty
would be preferable in patients at highest risk for in-
tracranial hemorrhage.29 
A further and perhaps unexpected finding was the
timing of the benefit of angioplasty (Fig. 1). If the
mechanism of this benefit is the early restoration of
TIMI grade 3 flow, the importance of which was
demonstrated in the GUSTO-I trial, then a benefit
should have been evident within 24 hours.23 The de-
layed benefit, particularly with respect to reinfarc-
tion, suggests that either spontaneous or procedure-
related reinfarction between day 5 and day 10 in the
t-PA group accounted for much of the difference in
outcome, as Stone and colleagues also suggested.30 
The attenuation of the benefit of angioplasty at
six months is notable. Smaller trials have reported
mixed results after discharge from the hospital.31-33
This finding may have been a consequence of the
relatively high rate of coronary reocclusion after an-
gioplasty, which has been noted in serial angiographic
studies.34 
Given the striking reduction in adverse outcomes
in patients treated with inhibitors of the platelet
glycoprotein IIb/IIIa receptor as an adjunct to an-
gioplasty35,36 and the possible benefit of these agents
combined with thrombolytic therapy,37 the possi-
ble improvement in outcome early after infarction
with primary stenting as compared with angioplas-
ty alone,38-41 and the reduction in intermediate-
term revascularization in selected patients treated
with stents,42,43 this study should be regarded as only
a step in the continued development of optimal re-
perfusion strategies. The speed, completeness, and
durability of reperfusion, and thus outcomes for pa-
tients, will probably improve with both angioplasty
and thrombolytic therapy.
At present, physicians deciding which therapy to
offer a patient who is eligible for either treatment
should return to fundamentals established in multi-
ple large studies. The rapid restoration of brisk an-
tegrade coronary flow is critical in reducing mortal-
ity.1,2 The time from presentation to angioplasty in
GUSTO IIb (1.9 hours) was greater than the time
from randomization in the PAMI and Dutch trials
(1.0 hour in each)4,5 and nearly the same as in the
more broadly representative Second National Reg-
istry of Myocardial Infarction (2.0 hours).17 If a
skilled cardiologist is readily available and the pa-
tient can be treated rapidly, angioplasty may be pref-
erable. Patients with severe hypertension, advanced
age, or symptomatic cerebrovascular disease should
also be treated with angioplasty, if available, to lower
the risk of intracranial hemorrhage.29 In most situa-
tions, however, thrombolytic therapy should still be
regarded as an excellent strategy of reperfusion. The
important point is not to delay in restoring myocar-
dial reperfusion in suitable candidates with two at-
tractive alternatives.
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APPENDIX
The following centers and investigators collaborated in this study (values
in parentheses denote the number of patients enrolled). Principal Inves-
tigators: A. Betriu, H. Phillips, and S. Ellis. Steering Committee:
E. Topol (Study Chairman), R. Califf (Clinical Director, Coordinating
Center), F. Van der Werf (Director, Intermediate Coordinating Center),
A. Betriu (International Clinical Coordinator), D. Ardissino, P.W. Arm-
strong, P. Aylward, E. Bates, K. Beatt, J. Cheseboro, J. Col, S. Ellis,
H. Emanuelsson, V. Fuster, W.B. Gibler, J. Gore, A. Guerci, J. Hochman,
D. Holmes, N. Kleiman, D. Morris, K. Neuhaus, M. Ohman, M. Pfisterer,
H. Phillips, W. Rutsch, J. Simes, M. Simoons, A. Vahanian, W.D. Weaver,
and H. White. Coordinating Center: Duke University Medical Center,
Durham, N.C. — Clinician Coordinators: C. Granger, H. Phillips, J. Hoch-
rein, and R. Califf; Coordinators: B. Fraulo, I. Moffie, and L. Paraschos;
Statisticians: A. Stebbins, L. Woodlief, K. Lee, and K. Pieper; Electrocardio-
graphic Core Laboratory: G.S. Wagner (Director) and K. Gates. Angiograph-
ic Core Laboratory: Cleveland Clinic Foundation, Cleveland — S. Ellis
(Director), D. Debowey, R. Poliszczuk, and H. Vilsack. International:
Clinical Coordinator: A. Betriu, Spain; Coordinators: A. Luyten, Belgium;
L. Tobback, Belgium; M. Kava, Australia; and W. Sutherland, Canada.
Data Safety and Monitoring Committee: R. Frye (Chairman), M. Cheit-
lin, D. DeMets, L. Fisher, J. Hirsh, P. Serruys, and L. Walters.
United States (401 patients): North Memorial Hospital, Robbinsdale:
G. Hanovich and A. Antolick; Maine Medical Center, Portland: M. Kellett and
C. Berg; Wilson Memorial Hospital, Johnson City: N.M. Jamal and D. Whiting;
Mercy Hospital of Pittsburgh, Pittsburgh: V. Krishnaswami and A. Heyl; Lahey
Clinic Medical Center, Burlington: D. Gossman and M. Dorland; Duke Uni-
versity Medical Center, Durham: H. Phillips and E. Berrios; Presbyterian Hos-
pital, Albuquerque: H. White and R. Sexson; Lancaster General Hospital,
Lancaster: J. Ibarra and L. Frey; St. Mary’s Hospital, Tucson: L. Lancaster and
D. Lansman; Louisiana State University Medical Center, Shreveport: F. Sheri-
dan and R. McRae; Cleveland Clinic Foundation, Cleveland: S. Ellis and
S. Hejl; Robert W. Johnson Hospital, New Brunswick: S. Palmeri and L. Casaz-
za; York Hospital, York: W. Schrading and N. Sonin; McLellan Memorial
Veterans Affairs Hospital, Little Rock: D. Talley; University of Arkansas, Lit-
tle Rock: J. Talley and S. Ashcraft; Dartmouth–Hitchcock Medical Center,
Lebanon: N. Niles and R. Edkins; St. Joseph’s Hospital, Lancaster: J. Ibarra
and L. Hollywood; Cottonwood Hospital, Murray: G. Symkoviak and J. Pin-
cock; West Florida Hospital, Pensacola: D. Mishkel and J. Lehmann; Craw-
ford Long Hospital, Atlanta: D. Morris and R. Law-McKenzie; St. Joseph’s
Hospital, Savannah: P.C. Gainey and D. Baker; Fairview–Southdale Hospi-
tal, Edina: W. Maddox and C. Sturm; Santa Rosa Memorial Hospital, Santa
Rosa: R. Miller and S. Woods; Audubon Regional Medical Center, Louis-
ville: D. Dageford and J. Hanrahan; Hershey Medical Center, Hershey:
I. Gilchrist and H. Zimmerman; E. Alabama Medical Center, Opelika:
M. Williams and G. Stegall; St. Mark’s Hospital, Salt Lake City: J. Perry and
W. Schvaneveldt; Oakwood Hospital, Dearborn: A. Riba and C. Draus;
Shadyside Hospital, Pittsburgh: J.D. O’Toole and K. Sudina; Morton Plant
Hospital, Largo: D. Spriggs and F. Schulz; Memorial Mission Hospital,
Asheville: W.T. Maddox and S. Allan; Good Samaritan Hospital, Dayton:
D. Hammer and C. White; University Community Hospital, Tampa:
J. Smith and L. Harrah; Proctor Hospital, Peoria: P. Schmidt and C. Ness;
St. Joseph’s Medical Center, Albuquerque: J. Kaplan and G. Steffans; Roches-
ter General Hospital, Rochester: G. Gacioch and V. Chiodo; and Roper Hos-
pital, Charleston: K. Hanger and C. Chapuseaux. Spain (239 patients):
Hospital Gregorio Marañon, Madrid: E. Garcia Fernandez; Hospital Clinico
y Provincial, Barcelona: A. Betriu; and Hospital Clinico Universitario, Val-
ladolid: F. Fernadez Aviles. Belgium (166 patients): Hôpital de la Cita-
delle, Liège: J. Boland; Cliniques Saint-Luc, Brussels: J. Col; Clinique Saint-
Jean, Brussels: M. Castadot; Centre Hospitalier Universitaire Sart Tilman,
Liège: V. Legrand; and Cliniques Universitaires de Mont-Godinne, Yvoir:
E. Schroeder. Italy (121 patients): Ospedale Borgo Trento, Verona: C. Vas-
sanelli; Ospedale Maggiore, Novara: C. Cernigliaro; Ospedale de Circolo,
Varese: S. Repetto; and Ospedali Riuniti, Bergamo: O. Valsecchi. Germany
(64 patients): Krankenhaus am Urban, Berlin–Kreuzberg: H. Topp; and
Freie Universität Berlin, Berlin: W. Rutsch. Sweden (62 patients): Sahlgren-
ska Hospital, Göteborg: H. Emanuelsson; and Mölndal Hospital, Mölndal:
M. Risenfors. Switzerland (46 patients): Kantonspital, Basel: M. Pfisterer;
Universitatsspital, Zurich: F.W. Amann; and Hôpital Cantonal, Geneva:
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P. Urban. Australia (37 patients): Flinders Medical Centre, Adelaide: P. Ayl-
ward and S. Dolan; Royal North Shore Hospital, St. Leonards: G. Nelson
and R. Scammell; and Prince Charles Hospital, Chermside: N. Bett and
C. Newitt. Canada (2 patients): University of Ottawa, Ottawa: M. Labinza
and S. Kearns.
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